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Abstract Since the generation upon cell stimulation of the
second messenger ceramide has been reported to occur in an
endosomal/lysosomal compartment, we investigated whether
ceramide formed in the lysosomes can escape this compartment.
The metabolic fate of radiolabelled ceramide produced by
intralysosomal hydrolysis of LDL-associated [ceramide-
3H]sphingomyelin or [stearoyl-1-14C]sulfatide was examined in
fibroblasts from control individuals and a patient with inborn
lysosomal ceramidase deficiency (Farber disease). The behavior
of this radioactive ceramide was compared to that of a
fluorescent (lissamine-rhodaminyl) ceramide analogue deriving
from sulfatide degradation. While in Farber cells the natural,
radiolabelled ceramide remained completely undegraded and
accumulated in the lysosomes, the fluorescent derivative was
rapidly converted to sphingomyelin. These findings strongly
suggest that, in contrast to fluorescent derivatives, endogenous
long-chain ceramide is unable to exit from lysosomes, therefore
making the lysosomal ceramide unlikely to be a biomodulatory
molecule.
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1. Introduction
Ceramide (N-acyl-sphingosine) is the backbone of all sphin-
golipids, which are essential constituents of eukaryotic mem-
branes [1,2]. Ceramide is a precursor in the biosynthesis of all
complex sphingolipids, as well as a product of their degrada-
tion. Recently, this lipid has emerged as an important intra-
cellular second messenger, playing a key role in the signal
transduction pathways of an increasing number of extracellu-
lar agents [3^6]. So far, sphingomyelin (SM, ceramide phos-
phocholine), a major structural component of the mammalian
cell plasma membrane [7], has been proposed as the only
sphingolipid source of the signalling ceramide.
While the biological e¡ects of ceramide have been well
characterized and some of its intracellular targets identi¢ed
[3^6], the subcellular site of the generation of this lipid second
messenger still remains controversial. In particular, it has been
proposed that various biological responses are mediated by
the formation of ceramide in acidic, endosomal/lysosomal
compartments [8,9]. This model implies that the ceramide gen-
erated at this site is able to escape these compartments in
order to physically interact with its molecular targets (which
are not known to display an endosomal/lysosomal location).
Consistent with this view, £uorescent short-chain analogues of
ceramide seem to get across the lysosomal membrane [10^12].
However, the question whether natural, long-chain ceramide
undergoes the same metabolic routing had not been investi-
gated.
In the present study, we examined whether the ceramide
formed in the lysosomes of cells having either a normal or a
totally defective activity of lysosomal ceramidase (i.e. cells
derived from Farber disease [13]) can get across the lysosomal
membrane. Evidence is provided that, in contrast to ceramide
derivatives labelled with a highly polar £uorescent probe, nat-
ural ceramide is unable to escape the lysosomal compartment.
The implications of these ¢ndings with regard to the putative
role of lysosomal ceramide in signal transduction phenomena
are discussed.
2. Materials and methods
2.1. Chemicals
[ceramide-3H]Sphingomyelin ([ceramide-3H]SM, 400 mCi/mmol),
prepared by catalytic tritiation of bovine brain SM, was obtained
from CEA (Gif-sur-Yvette, France) [14]. Radiolabelled ceramide
was obtained by hydrolysis of [ceramide-3H]SM using Bacillus cereus
sphingomyelinase (Sigma, Lisle d’Abeau, France) and was puri¢ed by
TLC. [stearoyl-1-14C]Sulfatide (55 mCi/mmol) was purchased from
Aldrich (St. Louis, MO). N-Lissamine-rhodaminyl-(12-aminododeca-
noyl)-sphingolipids were synthesized as previously reported [15,16].
Silica gel 60 TLC plates (Art. 5721), TLC aluminium sheets (Art.
5553) and solvents were from Merck (Darmstadt, Germany).
DMEM Glutamax, penicillin, streptomycin, and trypsin-EDTA were
from Gibco BRL (Cergy-Pontoise, France); FCS was from Boehr-
inger-Ingelheim (Gagny, France) and the serum substitute, Ultroser
HY, from IBF (Villeneuve-la-Garenne, France).
2.2. Cell lines and cell culture
Human skin ¢broblasts were derived from normal individuals, ho-
mozygous patients a¡ected with late infantile metachromatic leuko-
dystrophy (line Ale) or with Farber disease (line Moh). Fibroblasts of
this Farber patient were previously shown to have a de¢cient (3.5%)
acid ceramidase activity and to store large amounts of ceramide
[17,18]. Alternatively, SV40-transformed ¢broblasts from this patient
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and from control individuals were used [19]. Cells were grown as
reported [19].
2.3. Preparation of LDL-associated [ceramide-3H]SM and
[3H]ceramide
[ceramide-3H]SM-labelled LDL and [3H]ceramide-labelled LDL
were prepared according to a previously reported procedure [14]. Al-
ternatively, [3H]ceramide-labelled LDL was prepared by incubating
for 4 h at 37‡C the LDL labelled with [ceramide-3H]SM in the pres-
ence of B. cereus sphingomyelinase (1.5 U/mg LDL, in 5 mM MgCl2,
0.15 M NaCl bu¡er, pH 7.4) to completely convert the SM to ceram-
ide, and then by reisolating the LDL by ultracentrifugation.
2.4. Incubation of intact cells with sphingolipids
Before the experiments were initiated, the cells were grown for 24 h
in DMEM medium containing 2% Ultroser HY, a serum substitute
devoid of lipoproteins. Then, cells were incubated at 37‡C for the
indicated periods with medium containing 2% Ultroser and LDL-as-
sociated [ceramide-3H]SM or [3H]ceramide (the ¢nal concentration of
LDL in the incubation medium averaged 50 Wg apoB/ml, i.e. 500 000
dpm/ml) or LR12-CS (5 nmol/ml, introduced in ethanolic solution), or
in the presence of 10% FCS containing [stearoyl-1-14C]sulfatide
(300 000 dpm/ml, also introduced in ethanolic solution). At the end
of the ‘pulse’ period, cells were brie£y washed at 37‡C in medium
containing 10% FCS. Fresh medium supplemented with 10% FCS
was added to the cells and incubation continued for the indicated
times. Then cells were washed thrice with phosphate bu¡ered saline
(PBS) containing BSA (2 mg/ml) and twice with PBS alone, and
harvested using a rubber policeman. The cell pellets were stored at
320‡C.
2.5. Subcellular fractionation studies
After a 24 h incubation with LDL-associated [ceramide-3H]SM,
followed by a 24 h chase, cells were washed with PBS, trypsinized,
washed again and fractionated as described [20]. Postnuclear particles
were resuspended in 0.6 ml of homogenization bu¡er adjusted with
sucrose to a density of 1.3 g/ml, and layered under a continuous
gradient of sucrose in homogenization bu¡er, prepared from two
5.5 ml solutions with densities of 1.1 and 1.3 g/ml. After centrifuga-
tion at 4‡C and 50 000Ug for 18 h in a Kontron TST41.14 swinging
rotor, 8^10 fractions were collected from the tube bottom, and the
density was determined. The fractions were analyzed for radioactivity,
protein content and marker enzymes: N-acetyl-L-hexosaminidase and
succinate-tetrazolium reductase [14].
2.6. Lipid extraction and analyses
Cell pellets were homogenized in 0.6 ml distilled water and the
lipids extracted as described [14,17,18]. Lipids were resolved by ana-
lytical TLC developed either in chloroform/methanol/water (100:42:6,
v/v) up to 2/3 of the plate and then in chloroform/methanol/acetic acid
(94:1:5, v/v) for radioactive lipids, or in chloroform/ethyl acetate/n-
butanol/0.25% KCl/methanol (25:25:25:9:16, v/v) for LR12-lipids.
The distribution of the radioactivity on the plate was analyzed using
a Berthold LB 2832 radiochromatoscan. The various metabolic prod-
ucts were scraped and quanti¢ed by liquid scintillation or spectro-
£uorometry.
3. Results
In previous studies [17], we identi¢ed a patient (Moh) af-
fected with a very severe form of Farber disease. Cultured
primary skin ¢broblasts of this patient, who died at 3 days
of age, exhibited a very high accumulation of ceramide, sug-
gesting little (if any) residual acid ceramidase activity [17,18].
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Fig. 1. Thin layer chromatogram of LR12-sphingolipids extracted
from Farber disease ¢broblasts incubated with LR12-ceramide.
SV40-transformed ¢broblasts from a control individual (N, lanes 4
and 7) and from a patient with Farber disease (F, lanes 3 and 6),
and untransformed ¢broblasts from a patient with metachromatic
leukodystrophy (ML, lanes 2 and 5) were incubated for 72 h with
5 WM LR12-CS. Then, the culture medium was collected and the
cells were washed and harvested. The lipids present both in the cells
(lanes 2^4) and the culture media (lanes 5^7) were extracted and an-
alyzed by TLC as described in Section 2. LR12-sphingolipid stand-
ards were simultaneously separated (STD, lane 1). The TLC plate
was photographed under UV illumination. These data are represen-
tative of four independent experiments. SM, sphingomyelin; CS, sul-
fatide; Glc/GalCer, glucosyl/galactosylceramide; FA, fatty acid;
Cer, ceramide.
Fig. 2. Degradation of LDL-associated [ceramide-3H]SM by normal but not Farber disease SV40-transformed ¢broblasts. SV40-transformed ¢-
broblasts from a control individual (open symbols) and from a patient with Farber disease (¢lled symbols) were incubated for 24 h with 0.6
WM LDL-associated [ceramide-3H]SM. Then, at time zero the cells were washed and further incubated in medium devoid of radioactive lipid.
At the indicated times, cells were washed and the lipids extracted and analyzed as described in Section 2. The amounts of total, including newly
synthesized, SM (A) and ceramide products (C) [14,19] are expressed as percentage of the total cell-associated radioactivity, whereas the levels
of intact [ceramide-3H]SM (B) are expressed as percentage of the total lipid products of SM hydrolysis, i.e. by neglecting the SM itself but con-
sidering the ceramide as the substrate. At each time point, the data correspond to means þ S.D. of four separate experiments, except at time
7 days and for control cells (two separate experiments). The S.D. are too small to be seen.
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This cell line was therefore selected for the experiments shown
in the present study.
Initial experiments aimed at examining the metabolic fate of
a polar £uorescent analogue of ceramide, LR12-ceramide in
normal and Farber ¢broblasts. In order to selectively target
this lipid to the lysosomes, a metabolic precursor, LR12-sul-
fatide, was employed since previous observations had demon-
strated that this sphingolipid is taken up by ¢broblasts and
hydrolyzed in the lysosomes [16,21]. As illustrated in Fig. 1
(lane 4), this £uorescent sulfatide was degraded by normal
cells to galactosylceramide (faint band) and then to ceramide,
which was converted to LR12-SM, presumably in the Golgi
compartment [22^25]. This newly synthesized SM was released
into the culture medium (lane 7). In contrast, in cells genet-
ically de¢cient in the lysosomal cerebroside sulfatase activity,
i.e. cells derived from a patient with metachromatic leukodys-
trophy, the LR12-sulfatide remained completely intact (Fig. 1,
lanes 2 and 5), which corroborates the idea that the break-
down of this sphingolipid occurs only in the lysosomes. Of
particular interest, ¢broblasts from the severely a¡ected Farb-
er disease patient behaved exactly as control cells (lanes 3 and
6). Quantitative £uorometric determinations indicated that in
control and Farber cells, the intracellular amounts of LR12-
ceramide (35 vs. 38%) and LR12-SM (4% in both cases) were
comparable. Also, Farber cells released into the medium sim-
ilar amounts of LR12-SM as control cells. As previously ob-
served [16,21], no free £uorescent fatty acid was detected.
Since the above observations on Farber ¢broblasts,
although consistent with data in the literature obtained with
various £uorescent ceramides on other cell types [22,26,27],
did not conform with the lysosomal storage of ceramide
seen in this lipidosis [13,19], we next investigated the metabol-
ic fate of naturally occurring, long-chain ceramides. Normal
and Farber SV40-transformed ¢broblasts were ¢rst incubated
with LDL-associated [ceramide-3H]SM in order to selectively
target the sphingolipid to the lysosomes [14], then chased.
Under these conditions, the ceramide released from radiola-
belled SM was rapidly degraded in control cells (Fig. 2B),
giving rise to various metabolic products (Fig. 2C) including
newly synthesized SM (Fig. 2A) [14,17,19]. In contrast, in
¢broblasts from a Farber disease patient, no signi¢cant deg-
radation of [ceramide-3H]SM could be observed, even after
one week of chase (Fig. 2). In addition, the cell-associated
radioactivity in these lipidotic cells remained constant over
this chase period, strongly suggesting the absence of hydrol-
ysis and e¥ux of undegraded ceramide. Very similar results
were obtained when non-transformed cells were used (Table
1), or when cells were loaded with LDL-associated radiola-
belled ceramide, i.e. either lipoproteins labelled with [ceram-
ide-3H]SM and then treated with bacterial sphingomyelinase
or LDL directly labelled with [3H]ceramide (Table 1). More-
over, Farber cells fed the natural, radiolabelled sulfatide
([stearoyl-1-14C]sulfatide), the degradation of which is known
to occur in the lysosomes [28,29], also accumulated the sub-
sequently released ceramide (Table 1).
To examine the intracellular location of the radiolabelled,
undegraded ceramide in Farber cells, subcellular fractionation
experiments were performed after a chase period on cells
loaded with LDL-associated [ceramide-3H]SM. As shown in
Fig. 3, a considerable part of the radioactivity present in con-
trol ¢broblasts was distributed in fractions other than lyso-
somes because of extensive metabolism of SM and ceramide,
and reincorporation in other organelles of intermediate equi-
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Table 1
Fate of natural, radiolabelled ceramide from various sources in non-transformed and SV40-transformed ¢broblasts from Farber disease
Cell line Time of chase (days) Non-transformed SV40-transformed
[cer-3H]SM [cer-3H]SM+SMase [3H]cer [stearoyl-14C]CS
Farber 0 99 87; 90 83 þ 2 (4) 89; 92
1 98 88 þ 6 (3) 83 þ 2 (4) ND
2 99 90 þ 3 (3) 83 þ 5 (3) 87; 87
4 ND 91 þ 3 (3) 89; 76 ND
Control 0 5.1* 20 þ 5 (3) 48 þ 5 (3) 19; 28
Non-transformed or SV40-transformed ¢broblasts from control individuals and from a patient with Farber disease were incubated for 24 h with 0.6
WM LDL-associated [ceramide-3H]SM ([cer-3H]SM), B. cereus sphingomyelinase-treated LDL-associated [ceramide-3H]SM ([cer-3H]SM+SMase),
LDL-associated [3H]ceramide ([3H]cer), or [stearoyl-14C]sulfatide ([stearoyl-14C]CS), washed and chased for the indicated intervals. Lipids were then
extracted and analyzed as described in Section 2. The amounts of intact radioactive ceramide are expressed as percentages of either total cell-
associated radioactivity (for cells loaded with [3H]ceramide), or total lipid products (including fatty acid) of SM or galactosylceramide hydrolysis to
consider the ceramide as the starting substrate.
ND, not determined. The asterisk refers to other published data [14,17].
Fig. 3. Subcellular fractionation of ¢broblasts from a control subject
and a Farber disease patient incubated with LDL-associated [ceram-
ide-3H]SM. SV40-transformed ¢broblasts derived from a control in-
dividual (left) and a patient with Farber disease (right) were pulsed
for 24 h with LDL-associated [ceramide-3H]SM, washed and further
incubated for 24 h. Then, cells were homogenized, and postnuclear
particles were prepared and layered under a continuous sucrose den-
sity gradient [20]. After centrifugation, eight fractions were collected
and analyzed for density, radioactivity (CER), lysosomal (L-hexosa-
minidase; L-Hex) and mitochondrial (INT-succinate reductase)
markers. The data correspond to a representative experiment; simi-
lar results were obtained in three other separate experiments.
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librium density. In marked contrast, the radioactivity in Farb-
er cells (which is mainly contributed by undegraded ceramide)
clearly peaked in the lightest fraction, which was most coen-
riched in the lysosomal marker. There was also a considerable
lightening of all lysosomes of Farber ¢broblasts, as already
reported [30]. This probably results from the storage of the
hydrophobic lipid, ceramide. Taken together, the above data
indicate that, independently of its origin, the natural, long-
chain ceramide reaching or formed in the lysosomes of acid
ceramidase-de¢cient cells accumulates there.
4. Discussion
Ceramide and some other sphingolipid derivatives are
emerging as second messengers which play key signalling roles
in a variety of cellular systems and exhibit pleiotropic biolog-
ical responses [3^6]. While intracellular ceramide can originate
from di¡erent sources (e.g. glycolipids or SM) and from a
speci¢c lipid (e.g. SM) through di¡erent enzymes exhibiting
distinct subcellular localizations, the precise site of formation
of the ceramide having signalling functions still remains a
matter of debate. For instance, the signalling ceramide has
been proposed to be generated from SM at the plasma mem-
brane, in the inner lea£et [25,31] or in caveolae [32], and/or in
the endosomal/lysosomal compartment [8,9]. Should the cer-
amide be formed in the lysosomes, this lipid must be assumed
to be able to leave this compartment in order to exert its
signalling functions. However, the question whether natural
ceramide can indeed get across the lysosomal membrane has
never been addressed. This issue is of crucial importance for a
better understanding not only of the pathophysiology of in-
herited lipidoses such as Farber disease, but also of the mode
of action of ceramide as an intracellular second messenger
molecule.
Elegant studies by Pagano and coworkers using short-chain
£uorescent (C6-NBD) derivatives of ceramide have suggested
that ceramide could escape the lysosome and travel to the
Golgi apparatus where it is metabolized to SM or glucosylcer-
amide [12,22]. However, as pointed out by these authors, the
mechanisms of metabolism and transport of these analogues
may be unique to the short-chain sphingolipids because of
their ability to undergo spontaneous monomeric transfer.
The present and previous studies [16,21,27] indicate that the
LR12-ceramide derivative exhibits a similar behavior, suggest-
ing that in addition to the acyl chain length the presence of a
polar £uorescent group can dramatically in£uence the tra⁄ck-
ing route of sphingolipids. From the data obtained in this
work and previous observations on either human ¢broblasts
[16,21] or rat oligodendrocytes [27] incubated either in the
absence or presence of serum, the intracellular transport and
metabolism of LR12-glycolipids can be interpreted as follows.
After uptake, LR12-CS is internalized in the lysosomal com-
partment where it is degraded into ceramide. Evidence that
hydrolysis of LR12-CS takes place solely in the lysosomes is
provided by the complete inability of cerebroside sulfatase-
de¢cient cells to metabolize this lipid. The subsequently
formed LR12-ceramide, once transported to the Golgi com-
partment, is converted to SM, which reaches the plasma mem-
brane by a vesicle-mediated process. At the cell surface,
LR12-SM is released into the culture medium by back ex-
change, most probably because of the presence of the polar
£uorophore. These metabolic routes were indistinguishable in
normal and Farber disease ¢broblasts, indicating that the traf-
¢cking of LR12-sphingolipids is not a¡ected by the complete
de¢ciency of lysosomal ceramide degradation.
The present study provides evidence that, in marked con-
trast to the behavior of the £uorescent ceramide derivative,
natural radiolabelled ceramide is unable to leave the lyso-
some. This conclusion is supported by the following observa-
tions: (i) in normal ¢broblasts, the long-chain ceramide deliv-
ered to, or formed within, lysosomes is rapidly degraded and
its catabolic products are reutilized [14,17,29]; (ii) in severely
de¢cient Farber cells, no degradation of lysosomal ceramide
can be detected whatever its source (e.g. ceramide or SM
delivered to the lysosomes through the apoB/E receptor-medi-
ated endocytic pathway, or cerebroside sulfate); (iii) in Farber
cells, natural ceramide accumulates in the lysosomal compart-
ment. These ¢ndings lead to the conclusion that natural, long-
chain ceramide cannot leave the lysosomes and that further
catabolism to sphingosine and fatty acid, via the action of
acid ceramidase, is needed to generate compounds able to
escape these acidic compartments. This view is further
strengthened by a recent report demonstrating accumulation
in Farber ¢broblasts of endogenously labelled ceramide [33].
The fact that natural ceramide is unable to escape the ly-
sosomes has several implications. First, it demonstrates that at
least in ¢broblasts endogenous, long-chain ceramide under-
goes di¡erent tra⁄cking routes than £uorescent and/or
short-chain ceramide derivatives. Therefore, although £uores-
cent analogues of sphingolipids have proven useful in delin-
eating major pathways for sphingolipid synthesis, transport
and secretion [11,12], data obtained with such derivatives
should still be interpreted with caution, because they may
not accurately re£ect the fate of endogenous lipids. Second,
di¡erences in the severity of lysosomal ceramide storage ob-
served among di¡erent Farber disease patients [17,19,33] are
probably related to subtle di¡erences in the residual e¡ective
acid ceramidase activity rather than defects or variations in
the e¥ux of ceramide. Third, because of its inaccessibility to
its cellular targets, ceramide produced in lysosomes is unlikely
to play a signalling role. This would suggest that, if cell stim-
ulation results in the activation of an acidic sphingomyelinase,
the ceramide which is generated to act as a second messenger
is probably not located in mature lysosomes but in another, as
yet non-de¢ned, subcellular compartment enriched in the
above acidic sphingomyelinase.
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